Abstract: In some aspects, provided herein are antibodies that bind to PD-1. Antibodies provided herein, in some cases, agonize PD-1 signaling. Antibodies provided herein, in some cases, have modified Fc region. In other aspects, provided herein are compositions, methods of use, methods of making, and kits relating to antibodies that bind to PD-1.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding, the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.

Abstract: A disc caddy and associated method for handling is characterized by a disc cassette having opposing longitudinal side walls joined to opposing lateral end walls forming a substantially rectangular structure defining open first and second ends. A first removable cover is provided for closing the first end, and a second removable cover is provided for closing the second end. The second removable cover defines barb members that latchingly engage respective strikes defined by the first removable cover that extend substantially parallel to the end walls. The disc cassette has protuberant features defining reference hold-down surfaces, and the first removable cover defines clearance apertures through which the hold-down surfaces extend.

Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects.

Abstract: Anti-MCP-1/CCR2 antagonist therapy is provided for the control or reversal of fibrosis related diseases, including, e.g., but not limited to MCP-1/CCR2 antagonist therapy for the modulation of profibrotic markers associated with fibrotic processes including collagen matrix deposition and alveolar collapse.

Abstract: The present invention relates to compositions and methods for treating at least one IL-4 or IL-13 fibrosis related condition or pathology, including therapeutic compositions, formulations, methods and devices.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Antigens useful for raising antibodies against human resistin are also disclosed.

Abstract: A disc caddy and associated method for handling is characterized by a disc cassette having opposing longitudinal side walls joined to opposing lateral end walls forming a substantially rectangular structure defining open first and second ends. A first removable cover is provided for closing the first end, and a second removable cover is provided for closing the second end. The second removable cover defines barb members that latchingly engage respective strikes defined by the first removable cover that extend substantially parallel to the end walls. The disc cassette has protuberant features defining reference hold-down surfaces, and the first removable cover defines clearance apertures through which the hold-down surfaces extend.

Abstract: Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects.